Paul Marcoux

Centre National de la Recherche Scientifique

Also affiliated with Université Toulouse III - Paul Sabatier, Inserm, Université Fédérale de Toulouse Midi-Pyrénées, Centre de Recherches en Cancérologie de Toulouse

EngineeringMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Concurrent osimertinib plus gefitinib for first-line treatment of EGFR-mutated non-small cell lung cancer (NSCLC).”.

Concurrent osimertinib plus gefitinib for first-line treatment of EGFR-mutated non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.9507

N/A

1.5DataRank · unranked

39 citations

Daniel B. Costa, Cloud P. Paweletz, Mark M. Awad, Paul Marcoux, Deepa Rangachari +13 more

85 | PATIENT‐DERIVED LYMPHOMA SPHEROIDS AS PRECLINICAL MODELS FOR PREDICTING PATIENT RESPONSES TO ADVANCED THERAPIES IN B‐NHL: EXAMPLE OF GLOFITAMAB IN FOLLICULAR LYMPHOMA

Hematological Oncology(2025)10.1002/hon.70093_85

N/A

0DataRank · unranked

0 citations

Franco Gava, Christina Schniederjohann, Pauline Gravelle, Marie Tosolini, S. Quertinmont +14 more